Daniel E. Knutson

621 total citations
28 papers, 437 citations indexed

About

Daniel E. Knutson is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Biological Psychiatry. According to data from OpenAlex, Daniel E. Knutson has authored 28 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 17 papers in Cellular and Molecular Neuroscience and 6 papers in Biological Psychiatry. Recurrent topics in Daniel E. Knutson's work include Neuroscience and Neuropharmacology Research (16 papers), Receptor Mechanisms and Signaling (9 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Daniel E. Knutson is often cited by papers focused on Neuroscience and Neuropharmacology Research (16 papers), Receptor Mechanisms and Signaling (9 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Daniel E. Knutson collaborates with scholars based in United States, Austria and Serbia. Daniel E. Knutson's co-authors include James M. Cook, Werner Sieghart, Guanguan Li, Lih‐Chu Chiou, Jeffrey M. Witkin, Miroslav M. Savić, Mounira Banasr, Etienne Sibille, Leggy A. Arnold and Thomas D. Prévot and has published in prestigious journals such as Biological Psychiatry, Journal of Medicinal Chemistry and Cerebral Cortex.

In The Last Decade

Daniel E. Knutson

28 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel E. Knutson United States 13 239 185 67 65 59 28 437
Daniela Pechlivanova Bulgaria 13 272 1.1× 144 0.8× 108 1.6× 70 1.1× 63 1.1× 38 561
Lang Huang China 12 142 0.6× 148 0.8× 40 0.6× 99 1.5× 65 1.1× 23 444
Seong S. Shim United States 12 193 0.8× 136 0.7× 73 1.1× 61 0.9× 59 1.0× 15 451
Taiichiro Imanishi Japan 11 208 0.9× 168 0.9× 51 0.8× 38 0.6× 68 1.2× 17 422
José L. Góngora‐Alfaro Mexico 14 387 1.6× 185 1.0× 73 1.1× 59 0.9× 95 1.6× 46 677
Małgorzata Hołuj Poland 15 227 0.9× 228 1.2× 29 0.4× 107 1.6× 77 1.3× 21 537
Patrícia Miranda-Azpiazu Spain 9 187 0.8× 152 0.8× 33 0.5× 51 0.8× 42 0.7× 21 379
Raly James Perez Custodio South Korea 14 223 0.9× 87 0.5× 38 0.6× 52 0.8× 67 1.1× 37 431
Nichole M. Neugebauer‎ United States 18 451 1.9× 362 2.0× 68 1.0× 42 0.6× 79 1.3× 33 685
Maggie D. Lalies United Kingdom 12 315 1.3× 247 1.3× 75 1.1× 31 0.5× 31 0.5× 17 492

Countries citing papers authored by Daniel E. Knutson

Since Specialization
Citations

This map shows the geographic impact of Daniel E. Knutson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Knutson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Knutson more than expected).

Fields of papers citing papers by Daniel E. Knutson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Knutson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Knutson. The network helps show where Daniel E. Knutson may publish in the future.

Co-authorship network of co-authors of Daniel E. Knutson

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Knutson. A scholar is included among the top collaborators of Daniel E. Knutson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Knutson. Daniel E. Knutson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Ming Tatt, Daniel E. Knutson, James M. Cook, et al.. (2023). Cerebellar α6GABAA Receptors as a Therapeutic Target for Essential Tremor: Proof-of-Concept Study with Ethanol and Pyrazoloquinolinones. Neurotherapeutics. 20(2). 399–418. 13 indexed citations
2.
Knutson, Daniel E., Danijela Randjelović, Vladimir Dobričić, et al.. (2023). High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances. International Journal of Pharmaceutics. 633. 122613–122613. 7 indexed citations
3.
Knutson, Daniel E., Aleksandar Kremenović, Pegi Ahlin Grabnar, et al.. (2023). Freeze-dried nanocrystal dispersion of novel deuterated pyrazoloquinolinone ligand (DK-I-56-1): Process parameters and lyoprotectant selection through the stability study. European Journal of Pharmaceutical Sciences. 189. 106557–106557. 3 indexed citations
4.
Knutson, Daniel E., et al.. (2021). The α6 GABAA Receptor Positive Allosteric Modulator DK-I-56-1 Reduces Tic-Related Behaviors in Mouse Models of Tourette Syndrome. Biomolecules. 11(2). 175–175. 15 indexed citations
5.
Fee, Corey, Thomas D. Prévot, Keith A. Misquitta, et al.. (2021). Behavioral Deficits Induced by Somatostatin-Positive GABA Neuron Silencing Are Rescued by Alpha 5 GABA-A Receptor Potentiation. The International Journal of Neuropsychopharmacology. 24(6). 505–518. 31 indexed citations
6.
Knutson, Daniel E., et al.. (2021). Identification and Quantification of MIDD0301 Metabolites. Current Drug Metabolism. 22(14). 1114–1123. 2 indexed citations
7.
Knutson, Daniel E., Aleksandar Kremenović, Vladimir Dobričić, et al.. (2021). Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based Approach. Pharmaceutics. 13(8). 1188–1188. 7 indexed citations
8.
Duke, Angela N., V. V. N. Phani Babu Tiruveedhula, Daniel E. Knutson, et al.. (2021). Tolerance and dependence following chronic alprazolam treatment in rhesus monkeys: Role of GABAA receptor subtypes. Drug and Alcohol Dependence. 228. 108985–108985. 10 indexed citations
9.
Prévot, Thomas D., Akiko Sumitomo, Toshifumi Tomoda, et al.. (2020). Reversal of Age-Related Neuronal Atrophy by α5-GABAA Receptor Positive Allosteric Modulation. Cerebral Cortex. 31(2). 1395–1408. 23 indexed citations
10.
Li, Guanguan, et al.. (2020). The Effects of pH on the Structure and Bioavailability of Imidazobenzodiazepine-3-Carboxylate MIDD0301. Molecular Pharmaceutics. 17(4). 1182–1192. 6 indexed citations
11.
Yocum, Gene T., et al.. (2020). Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma Models. ACS Pharmacology & Translational Science. 3(6). 1381–1390. 6 indexed citations
12.
Knutson, Daniel E., Predrag Vulić, Danijela Randjelović, et al.. (2020). Nanocrystal dispersion of DK-I-56–1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance. European Journal of Pharmaceutical Sciences. 152. 105432–105432. 7 indexed citations
13.
Knutson, Daniel E., Jodi L. Smith, Xingjie Ping, et al.. (2020). Imidazodiazepine Anticonvulsant, KRM-II-81, Produces Novel, Non-diazepam-like Antiseizure Effects. ACS Chemical Neuroscience. 11(17). 2624–2637. 11 indexed citations
14.
Lee, Ming Tatt, Pi‐Chuan Fan, Daniel E. Knutson, et al.. (2020). α6GABAA Receptor Positive Modulators Alleviate Migraine-like Grimaces in Mice via Compensating GABAergic Deficits in Trigeminal Ganglia. Neurotherapeutics. 18(1). 569–585. 21 indexed citations
15.
Knutson, Daniel E., et al.. (2020). Improved Scale-up Synthesis and Purification of Clinical Asthma Candidate MIDD0301. Organic Process Research & Development. 24(8). 1467–1476. 12 indexed citations
16.
Biggerstaff, Andrew, Bronwyn M. Kivell, Jodi L. Smith, et al.. (2020). The α2,3-selective potentiators of GABAA receptors, KRM-II-81 and MP-III-80, produce anxiolytic-like effects and block chemotherapy-induced hyperalgesia in mice without tolerance development. Pharmacology Biochemistry and Behavior. 196. 172996–172996. 12 indexed citations
17.
Fan, Pi‐Chuan, Ming Tatt Lee, Werner Sieghart, et al.. (2018). The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation. Neuropharmacology. 140. 1–13. 22 indexed citations
18.
Knutson, Daniel E., Michael Rajesh Stephen, Vladimir Dobričić, et al.. (2018). Design and Synthesis of Novel Deuterated Ligands Functionally Selective for the γ-Aminobutyric Acid Type A Receptor (GABAAR) α6 Subtype with Improved Metabolic Stability and Enhanced Bioavailability. Journal of Medicinal Chemistry. 61(6). 2422–2446. 39 indexed citations
19.
Chiou, Lih‐Chu, Hsin‐Jung Lee, Margot Ernst, et al.. (2018). Cerebellar α6‐subunit‐containing GABAAreceptors: a novel therapeutic target for disrupted prepulse inhibition in neuropsychiatric disorders. British Journal of Pharmacology. 175(12). 2414–2427. 28 indexed citations
20.
Witkin, Jeffrey M., et al.. (2018). Rapid-Acting Antidepressants. Current Pharmaceutical Design. 24(22). 2556–2563. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026